The objective of current research was to study clinical-anamnestic characteristics in women with benign and precancerous processes in uterine cervix with combined uterine pathology (myoma, adenomyosis, endometrial hyperplasia and benign processes in uterine cervix). The results demonstrate that changes in uterine cervixes are more frequent in patients with combined uterine diseases compared with patients with monopathology.

In this work, we studied molecular-biological factors leading to cervical cancer. The clinicopathologic characteristics and immunohistochemical features of 185 patients with cervical pathologies associated with human papillomavirus infection were examined. Immunohistochemical features analyzed included histone deacetylases (HDAC1, HDAC2) and DNA methyltransferases (DNMT1, DNMT2). Strong correlations of these factors with cervical pathologies including malignancies were identified.

Uterine cervical cancer is on the 3rd place of cancerous diseases morbidity in Russia. Uterine cervical cancer is caused by persistent papillomavirus infection (PVI), therefore the main factor of uterine cervical cancer prevention is screening and vaccination against human papillomavirus (HPV). Uterine cervical cells infection with HPV is necessary, but not sufficient for their malignancy. Its important to provide adequate therapeutic measures to eliminate HIV from the organism, if infection already occurred. One of the effective methods of PVI complex conservative therapy is stimulation of cell immunity by use of natural purine analogue inosine pranobex (IP) as an immunostimulator. IP antivirus effect is associated with suppression of replication of DNA and RNA viruses by bounding to cell ribosome. Immunomodulating capacity of IP is characterized by stimulation of nonspecific immunity, enhanced interleukin production, increased antibodies synthesis, stimulation of chemotaxic and phagocytous activity of monocytes and macrophagues and polymorphonuclear cells. In present article data on open and double blind placebo-controlled studies of IP are summarized. These studies confirm IP efficacy in HPV-infection therapy.

spasmodic abdominal pain is a common complaint. Dysmenorrhea is one of the most important problems not only from medical, but also social point of view. Drotaverine hydrochloride is a potent smooth muscle spasmolytic agent. Objective: To evaluate the effectiveness of drotaverine in the daily practice management of spasmodic abdominal pain due to gastrointestinal, biliary, urological tract conditions and dysmenorrhea. Material and Methods: a multicenter, prospective, cross-sectional and longitudinal product registry (3 visits), non-interventional on the therapeutic strategy was conducted in Mexico, Kazakhstan, and Russia. Each investigator contributed at the 2 sequences: one cross-sectional, assessing physicians' interest for and knowledge of spasmodic abdominal pain management [Prescription Registry, PR] and longitudinal registry [LREG]: data on 25 consecutive eligible patients with spasmodic pain were recorded in the PR, and 5-day (+3) follow-up on the first 5 consecutive eligible patients receiving NOSPA ® . Pain was evaluated asking patients to rate the worst abdominal pain over the past 12 hours (11-point Numerical Pain Rating Scale, NPRS) and a Visual Analogue Scale (VAS) to evaluate the drotaverine onset of action. Only spontaneous adverse events reports were collected. Results: 208 physicians participated and included 5507 patients. 75% of them received drotaverine. Treatment was mostly prescribed in monotherapy (72%). From these patients, 1116 were included in the Longitudinal Registry (881 in the PP population) with a mean age of 34.2 ± 12.5 years. 86 % were females. Most suffered from dysmenorrhea (53%). They received drotaverine for 5.7±4 days. 89% were responders. Compared to the first evaluation, a statistical difference was observed in patients suffering from dysmenorrhea (p<0.0001). Conclusion: Results show that pain rapidly improves in patients suffering from spasmodic abdo minal pain when taking drotaverine in this open product registry conducted under conditions of real life. It is possible to discuss introduction of drotaverine in national guidelines for management of dysmenorrhea patients.

Violated antioxidant defenses in the pathogenesis of endometriosis are an important factor in the progression of the pathological process. Stimulation of natural antioxidant systems, the introduction of exogenous antioxidants, a number of vitamins and minerals is one of the key moments in the complex of conservative therapy and prevention of endometrioid process. The absence of significant side effects when using the majority of antioxidants, vitamins and minerals further argues the feasibility of their application.

Miscarriage is contributed by a number of different factors; among those, magnesium deficiency has a specific mechanism and polypathogenic effects. According to the results of numerous studies, magnesium medicines are effective in complex therapy of miscarriage as they affect key pathogenetic links. Prevention of miscarriage should be based on careful identification and elimination of the causes of miscarriage, examination and rehabilitation of nonpregnant women.

The need for post-abortion rehabilitation is conditioned by the frequency and relevance of delayed and long-term complications of induced abortions. Numerous studies demonstrate feasibility of using oral contraceptives for the prevention of adverse effects of abortion not only due to their good contraceptive effect, but also their ability to adequately rehabilitate the function of the hypothalamic-pituitary axis by adjusting hormone profile and levelling hormonal fluctuations, as well as their therapeutic effects, especially those produced by three-phase combined oral contraceptives.

Inflammatory diseases occupy leading positions in the list of gynaecological pathology. Inflammatory diseases of the pelvic organs (PID) recorded in 60-65% of women of reproductive age have a very negative impact on the female reproductive function, and cause chronic pelvic pain syndrome in 24% cases, infertility in 40%, miscarriage in 45%, and ectopic pregnancy in 3% of cases [1-3, 5, 7-9, 12, 13, 15-17, 20, 23]. Among inflammatory diseases in gynecology, endometritis and cervicitis account for about 70-80% of cases; however, the asymptomatic nature of the majority of endometritis and cervicitis cases (chronicity of the inflammatory process) and the fact of their being diagnosed only at routine gynecological exams, lead us to suggest that their incidence is much higher [4, 6, 10, 11, 14, 18, 19, 21, 22].

Uterine cervical cancer is on the 3rd place of cancerous diseases morbidity in Russia. Uterine cervical cancer is caused by persistent papillomavirus infection (PVI), therefore the main factor of uterine cervical cancer prevention is screening and vaccination against human papillomavirus (HPV). Uterine cervical cells infection with HPV is necessary, but not sufficient for their malignancy. Its important to provide adequate therapeutic measures to eliminate HIV from the organism, if infection already occurred. One of the effective methods of PVI complex conservative therapy is stimulation of cell immunity by use of natural purine analogue inosine pranobex (IP) as an immunostimulator. IP antivirus effect is associated with suppression of replication of DNA and RNA viruses by bounding to cell ribosome. Immunomodulating capacity of IP is characterized by stimulation of nonspecific immunity, enhanced interleukin production, increased antibodies synthesis, stimulation of chemotaxic and phagocytous activity of monocytes and macrophagues and polymorphonuclear cells. In present article data on open and double blind placebo-controlled studies of IP are summarized. These studies confirm IP efficacy in HPV-infection therapy.

The objective of current research was to study clinical-anamnestic characteristics in women with benign and precancerous processes in uterine cervix with combined uterine pathology (myoma, adenomyosis, endometrial hyperplasia and benign processes in uterine cervix). The results demonstrate that changes in uterine cervixes are more frequent in patients with combined uterine diseases compared with patients with monopathology.